Promoting Excellence in Education, Research,
and Patient Care in the Rapidly Evolving
Management of Gastrointestinal Cancer
International Society of
Gastrointestinal Oncology
isgioEstablished 2003
ISGIO President and President-elect
ISGIO President 2017-2019
Dr. Howard Hochster
Dr. Howard Hochster
Howard Hochster, MD
Rutgers Cancer Institute of New Jersey

Dr. Hochster is a well-known international figure in Gastrointestinal Cancer treatment and in developing new drugs to the clinic for these diseases. He has been recognized as on the “Top Oncology Doctors in America” and in the New York area for many years. He has chaired and published numerous clinical trials in the area of cancer drug development. He served as Principal Investigator for SWOG at Yale and its affiliated institutions, recipient of the Yale U10 grant, and GI Committee Chair for SWOG. He is also an active member of the Colon Task Force and a member of the CTEP GI Steering Committee. He was national director of Early Drug Development for Aptium Oncology Research Network and was a key member of the steering committee of the Aptium GI Cancer Consortium (AGICC). He is a medical director of the Chemotherapy Foundation of NYC and regularly chair the GI sessions at the annual meeting. He reviews grants regularly for NIH, Texas C-PRIT, and Cancer Research UK. He has served on the DSMB for international phase III trials. He has promoted cancer research and practice in New York City as President of the New York Cancer Society from 2005-2007.

ISGIO President-elect 2017-2019
Dr. Howard Hochster
Dr. Ghassan Abou-Alfa
Ghassan Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center

Ghassan Abou-Alfa joined Memorial Sloan-Kettering Cancer Center in 2001. He earned his medical degree from the American University in Beirut. In 1992, he joined the Yale School of Medicine for postdoctoral training. He received his MBA degree from Columbia University in 2016. Ghassan specializes in treating patients with gastrointestinal malignancies. His work focuses on investigating novel targeted therapies in clinical studies, and advocates for greater awareness of the disease's global impact. Ghassan is honored to chair the National Cancer Institute Hepatobiliary Task Force, and the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force. He also co-chairs the hepatobiliary cancers subgroup of the Alliance cooperative group.

Ghassan work focuses on hepatocellular carcinoma (HCC) which affects a diverse population from many cultures and economic backgrounds: truly a global disease. Ghassan continues his work to help advance the field. His research focuses on incorporating small biological molecules into standard cancer therapies. In recent years, he led the initial international effort that helped evaluate sorafenib in HCC. He later and in a trial led by the multi-cooperative groups, they investigated combining sorafenib with doxorubicin, an effort that is supported by the National Cancer Institute. Ghassan continues to lead several international efforts and is involved in conducting clinical trials with colleagues around the world. An effort that helps better understand the challenges of managing a disease with varying risk factors, in different regions of the world.

Ghassan has taken on an advocacy role as research funding has lagged despite the worldwide impact of this disease. He co-authored with hepatobiliary surgeon the chairman of surgery at U. Penn Ronald DeMatteo 100 Questions and Answers About Liver Cancer book, now in its third edition. He also co-authored with his wife Eileen O’Reilly, also a medical oncologist at Memorial Sloan Kettering Cancer Center, a similar book on bile ducts cancers now in its second edition.

Part of the global effort, Ghassan helped chair multiple training course for oncologists globally, and helped sustain monthly videolinked educational conferences with different regions of the world, for almost a decade now.